The synthetic lethal interaction between KRAS mutations and cyclin-dependent kinase (CDK) 4 and 6 inhibition highlights a promising therapeutic strategy for using CDK4/6 inhibitors in NSCLC (9). Here, KRAS is linked to non-small cell lung carcinoma.